Linezolid pharmacokinetics and pharmacodynamics in clinical treatment

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 4, 2011, Pages

  Dryden, Matthew S ^a  

^a ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

Author keywords

Concentrations; Oxazolidinones; PK PD

Indexed keywords

ACETIC ACID DERIVATIVE; ALUMINUM MAGNESIUM HYDROXIDE; AMINOETHOXYACETIC ACID; DRUG METABOLITE; GLYCINE DERIVATIVE; HYDROXYETHYLGLYCINE; LINEZOLID; PHENYLPROPANOLAMINE; PSEUDOEPHEDRINE; RIFAMPICIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANEMIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL MENINGITIS; BACTERIAL PERITONITIS; BACTERIAL SKIN DISEASE; BONE INFECTION; BRAIN VENTRICULITIS; CELLULITIS; CHILDHOOD DISEASE; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DIABETIC FOOT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TOLERABILITY; ENDOPHTHALMITIS; ENTERIC FEEDING; FOOD DRUG INTERACTION; GRAM POSITIVE INFECTION; GROUPS BY AGE; HUMAN; INFECTIOUS ARTHRITIS; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NEWBORN DISEASE; NONHUMAN; OBESITY; OPTIC NERVE DISEASE; PEPTOSTREPTOCOCCUS; PERIPHERAL NEUROPATHY; PLASMA PROTEIN BINDING; POSTOPERATIVE COMPLICATION; REVIEW; SEPSIS; SOFT TISSUE INFECTION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ACETAMIDES; ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; OXAZOLIDINONES;

EID: 79955498603     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr072     Document Type: Review

References (58)

1. MacGowan A. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 2003; 51 Suppl S2: ii17-25.
2. Stalker DJ, Jungbluth GL, Hopkins NK et al. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003; 51: 1239-46.
3. Gee T, Ellis R, Marshall G et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1843-5.
4. Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of 14C linezolid to healthy human subjects. Drug Metab Dispos 2001; 29: 1136-45.
5. Welshman IR, Stalker DJ, Wajsczuk CP. Assessment of absolute bioavailability and evaluation of the effect of food on oral bioavailability of linezolid. Anti-Infect Drugs Chemother 1998; 16 Suppl 1: 54.
6. Hendershot PE, Antal EJ, Welshman IR et al. Linezolid: pharmacokinetic and pharmacodynamic evaluation of co-administration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphan HBr. J Clin Pharmacol 2001; 41: 563-72.
7. Stalker DJ, Wajszczuk CP, Batts DH. Linezolid safety, tolerance and pharmacokinetics following oral dosing twice daily for 14.5 days. In: Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract A-115, p. 23. American Society for Microbiology, Washington, DC, USA.
8. Sisson TL, Jungbluth GL, Hopkins NK. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. J Clin Pharmacol 1999; 39: 1277-82.
9. Pharmacia Zyvox (linezolid) Clinical Information Pack (Jan. 2001). Pharmacia, Peapack, NJ, USA.
10. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-40.
11. Dehghanyar P, Bürger C, Zeitlinger M et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005; 49: 2367-71.
12. Islinger F, Dehghanyar P, Sauermann R et al. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents 2006; 27: 108-12.
13. Grunder G, Zysset-Aschmann Y, Vollenweider F et al. Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. Antimicrob Agents Chemother 2006; 50: 68-72.
14. Beringer P, Nguyen M, Hoem N et al. Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. Antimicrob Agents Chemother 2005; 49: 3676-81.
15. Kurien M, Sanders DS. Antibiotic prophylaxis after percutaneous endoscopic gastrostomy. BMJ 2010; 341: 55-6.
16. Stein GE, Schooley SL, Peloquin CA et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005; 39: 427-32.
17. Whitehouse T, Cepeda JA, Shulman R et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005; 55: 333-40.
18. Thallinger C, Buerger C, Plock N et al. Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 2008; 61: 173-6.
19. Adembri C, Fallani S, Cassetta MI et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008; 31: 122-9.
20. Buerger C, Plock N, Dehghanyar P et al. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006; 50: 2455-63.
21. Hallam MJ, Allen JM, James SE et al. Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 2010; 31: 207-9.
22. Cepeda JA, Whitehouse T, Cooper B et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother 2004; 53: 345-55.
23. Itani K, Dryden MS, Bhattacharyya H et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus. Am J Surg 2010; 199: 806-14.
24. Majcher-Peszynska J, Haase G, Sass M et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008; 64: 1093-100.
25. Traunmüller F, Schintler MV, Spende S et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents 2010; 36: 84-6.
26. Stein GE, Schooley S, Peloquin CA et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007; 60: 819-23.
27. Bassetti M, Righi E, Di Biagio A et al. Role of linezolid in the treatment of orthopedic infections. Expert Rev Anti Infect Ther 2005; 3: 343-52.
28. Falagas ME, Siempos II, Papagelopoulos PJ et al. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents 2007; 29: 233-9.
29. Metallidis S, Nikolaidis J, Lazaraki G et al. Penetration of linezolid into sternal bone of patients undergoing cardiopulmonary bypass surgery. Int J Antimicrob Agents 2007; 29: 742-4.
30. Kutscha-Lissberg F, Hebler U, Muhr G et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47: 3964-6.
31. Rana B, Butcher I, Grigoris P et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747-50.
32. Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50: 73-7.
33. Rayner CR, Forrest A, Meagher AK et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
34. Legout L, Valette M, Dezeque H et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother 2010; 65: 2224-30.
35. Soriano A, Ortega M, Garcia S et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007; 51: 2559-63.
36. Conte JE Jr, Golden JA, Kipps J et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002; 46: 1475-80.
37. Boselli E, Breilh D, Rimmele T et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005; 33: 1529-33.
38. Dumitrescu O, Badiou C, Bes M et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008; 14: 384-8.
39. Nathwani D, Morgan M, Masterton RG et al. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 2008; 61: 976-94.
40. Dryden M, Andrasevic AT, Bassetti M et al. A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice. Clin Microbiol Infect 2010; 16 Suppl 1: 3-30.
41. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 281-4.
42. Wagenlehner FM, Naber KG. New drugs for Gram-positive uropathogens. Int J Antimicrob Agents 2004; 24 Suppl 1: S39-43.
43. Brier ME, Stalker DJ, Aronoff GR et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47: 2775-80.
44. Fiaccadori E, Maggiore U, Rotelli C et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 2006; 21: 1402-6.
45. Schülin T, Thauvin-Eliopoulos C, Moellering RC et al. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1999; 43: 2873-6.
46. Paterson DL. Clinical experience with recently approved antibiotics. Curr Opin Pharmacol 2006; 6: 486-90.
47. DePestel DD, Peloquin CA, Carver PL. Peritoneal dialysis fluid concentrations of linezolid in the treatment of vancomycin-resistant Enterococcus faecium peritonitis. Pharmacotherapy 2003; 23: 1322-6.
48. Cottagnoud P, Gerber CM, Acosta F et al. Linezolid against penicillinsensitive and -resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 2000; 46: 981-5.
49. Gerber CM, Acosta F, Cottagnoud M et al. Evaluation of linezolid against penicillin sensitive and resistant pneumococci in the experimental meningitis model. In: Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1787, p. 81. American Society for Microbiology, Washington, DC, USA.
50. Mizell KN, Carter JE. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with linezolid. South Med J 2008; 101: 569-70.
51. Hachem R, Afif C, Gokaslan Z et al. Successful treatment of vancomycin-resistant Enterococcus meningitis with linezolid. Eur J Clin Microbiol Infect Dis 2001; 20: 432-4.
52. Beer R, Engelhardt KW, Pfausler B et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007; 51: 379-82.
53. Prydal JI, Jenkins DR, Lovering A et al. The pharmacokinetics of linezolid in the non-inflamed human eye. Br J Ophthalmol 2005; 89: 1418-9.
54. Falagas ME, Manta KG, Ntziora F et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 2006; 58: 273-80.
55. Kearns GL, Jungbluth GL, Abdel-Rahman SM et al. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther 2003; 74: 413-22.
56. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22 Suppl 9: S153-7.
57. Deville JG, Goldfarb J, Kaplan SL et al. The use of linezolid in the treatment of paediatric patients with infections caused by enterococci including strains resistant to vancomycin. J Antimicrob Chemother 2010; 65: 2267-70.
58. Smith PF, Birmingham MC, Noskin GA et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003; 14: 795-801.